The Journal of Organic Chemistry
Article
(0.078 g, 0.25 mmol) and pyrrolidine (0.035 g, 0.5 mmol). Rf =
0.45 (PE/EtOAc = 5:1); mp 166−168 °C; H NMR (400 MHz,
(s, 1H), 7.00 (s, 1H), 6.66 (s, 1H), 6.04 (s, 2H); 13C{1H} NMR
(101 MHz, CDCl3) δ 194.6, 152.6, 148.8, 147.3, 144.6, 139.7,
138.0, 133.3, 127.6, 125.3, 124.1, 106.1, 105.3, 102.6; IR (neat)
1655, 1587, 1513, 1470, 1396, 1334 cm−1; HRMS (ESI) m/z: [M +
H]+ calculated for C16H10NO5 296.0553; found 296.0552.
1
CDCl3) δ 8.04 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 8.3 Hz, 2H), 7.68
(s, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.20 (d, J = 7.7 Hz, 1H), 7.08 (s,
1H), 4.36 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H); 13C{1H}
NMR (101 MHz, CDCl3) δ 194.9, 166.2, 145.3, 142.7, 140.4, 136.5,
135.1, 130.4, 129.8, 129.2, 128.8, 127.2, 124.2, 123.1, 61.1, 14.4; IR
(neat) 1709, 1600, 1450, 1279 cm−1; HRMS (ESI) m/z: [M + H]+
calculated for C18H14ClO3 313.0626; found 313.0622.
Ethyl 4-(5-Oxo-5H-indeno[5,6-d][1,3]dioxol-6-yl)benzoate (2v).
This product was obtained as an amorphous purple solid (0.045 g,
55%) by using ethyl 4-((6-formylbenzo[d][1,3]dioxol-5-yl)ethynyl)-
benzoate (0.080 g, 0.25 mmol) and pyrrolidine (0.035 g, 0.5 mmol).
1
Ethyl 4-(5-Methoxy-1-oxo-1H-inden-2-yl)benzoate (2q). This
product was obtained as a crystalline red solid (0.049 g, 64%) by
using ethyl 4-((2-formyl-4-methoxyphenyl)ethynyl)benzoate (0.077
g, 0.25 mmol) and pyrrolidine (0.035 g, 0.5 mmol), and 1q (0.004
g) was recovered. Rf = 0.41 (PE/EtOAc = 5:1); mp 138−140 °C;
1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 8.5 Hz, 2H), 7.86 (d, J
= 8.4 Hz, 2H), 7.62 (s, 1H), 7.44 (d, J = 8.0 Hz, 1H), 6.67 (d, J =
2.1 Hz, 1H), 6.62 (dd, J = 8.0, 2.1 Hz, 1H), 4.37 (q, J = 7.1 Hz,
2H), 3.85 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (101
MHz, CDCl3) δ 195.2, 166.5, 165.1, 146.2, 142.4, 136.8, 136.0,
130.2, 129.9, 127.3, 125.4, 124.0, 111.4, 111.0, 61.2, 55.9, 14.5; IR
(neat) 1709, 1595, 1479, 1279 cm−1; HRMS (ESI) m/z: [M + H]+
calculated for C19H17O4 309.1121; found 309.1112.
Rf = 0.43 (DCM); mp 187−189 °C; H NMR (400 MHz, CDCl3)
δ 8.02 (d, J = 8.5 Hz, 2H), 7.81 (d, J = 8.5 Hz, 2H), 7.54 (s, 1H),
6.97 (s, 1H), 6.61 (s, 1H), 6.01 (s, 2H), 4.36 (q, J = 7.1 Hz, 2H),
1.38 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (101 MHz, CDCl3) δ
195.3, 166.6, 152.4, 148.2, 143.0, 140.1, 135.9, 134.6, 129.94,
129.87, 126.9, 125.3, 105.9, 105.0, 102.4, 61.2, 14.6; IR (neat) 2921,
1709, 1603, 1470 cm−1; HRMS (ESI) m/z: [M + H]+ calculated for
C19H15O5 323.0914; found 323.0906.
Ethyl 4-(6-Oxo-6H-indeno[4,5-d][1,3]dioxol-7-yl)benzoate (2w).
This product was obtained as an amorphous orange solid (0.061 g,
75%) by using ethyl 4-((4-formylbenzo[d][1,3]dioxol-5-yl)ethynyl)-
benzoate (0.081 g, 0.25 mmol) and pyrrolidine (0.036 g, 0.5 mmol).
Rf = 0.37 (PE/EtOAc = 5:1); mp 174−176 °C; 1H NMR (400
MHz, CDCl3) δ 7.83 (d, J = 8.6 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H),
7.56 (s, 1H), 6.92 (dd, J = 7.5, 0.6 Hz, 1H), 6.35 (d, J = 7.5 Hz,
1H), 5.84 (s, 2H), 4.16 (q, J = 7.1 Hz, 2H), 1.18 (t, J = 7.1 Hz,
3H); 13C{1H} NMR (101 MHz, CDCl3) δ 194.1, 166.5, 154.2,
141.6, 138.1, 136.6, 136.0, 130.2, 129.9, 127.2, 126.4, 122.0, 119.9,
106.6, 102.5, 61.3, 14.6; IR (neat) 1711, 1601, 1460, 1279 cm−1;
HRMS (ESI) m/z: [M + H]+ calculated for C19H15O5 323.0914;
found 323.0905.
Ethyl 4-(6-Fluoro-1-oxo-1H-inden-2-yl)benzoate (2r). This prod-
uct was obtained as an amorphous orange solid (0.041 g, 55%) by
using ethyl 4-((5-fluoro-2-formylphenyl)ethynyl)benzoate (0.074 g,
0.25 mmol) and pyrrolidine (0.035 g, 0.5 mmol). Rf = 0.50 (PE/
1
EtOAc = 5:1); mp 159−160 °C; H NMR (400 MHz, CDCl3) δ
8.03 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 7.72 (s, 1H),
7.17 (dd, J = 7.0, 2.1 Hz, 1H), 7.08−6.97 (m, 2H), 4.36 (q, J = 7.1
Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (101 MHz,
CDCl3) δ 195.1 (C-F, 4 JC‑F = 1.3 Hz), 166.4, 163.9 (C-F, 1 JC‑F
=
Ethyl 4-(3-Oxo-3H-cyclopenta[b]quinolin-2-yl)benzoate (2x).
This product was obtained as an amorphous red solid (0.053 g,
64%) by using ethyl 4-((3-formylquinolin-2-yl)ethynyl)benzoate
(0.082 g, 0.25 mmol) and pyrrolidine (0.036 g, 0.5 mmol). Rf =
0.29 (DCM); mp 239−241 °C; 1H NMR (400 MHz, CDCl3) δ
8.22 (d, J = 8.3 Hz, 1H), 8.11−8.08 (m, 3H), 7.98 (d, J = 8.6 Hz,
2H), 7.77 (d, J = 7.1 Hz, 1H), 7.74 (s, 1H), 7.67 (td, J = 7.6, 1.5
Hz, 1H), 7.58 (td, J = 7.5, 1.2 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H),
1.40 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (101 MHz, CDCl3) δ
194.1, 166.4, 153.4, 148.4, 144.4, 138.4, 135.1, 133.3, 132.1, 131.0,
130.4, 130.1, 129.6, 129.5, 129.0, 127.8, 127.3, 61.4, 14.6; IR (neat)
1711, 1591, 1445, 1274 cm−1; HRMS (ESI) m/z: [M + H]+
calculated for C21H16NO3 330.1125; found 330.1117.
Ethyl 4-(7-Oxo-7H-cyclopenta[b]pyridin-6-yl)benzoate (2y).
This product was obtained as an amorphous orange solid (0.052
g, 75%) by using ethyl 4-((3-formylpyridin-2-yl)ethynyl)benzoate
(0.070 g, 0.25 mmol) and pyrrolidine (0.036 g, 0.5 mmol). Rf =
0.28 (DCM/MeOH = 100:1); mp 140−142 °C; 1H NMR (400
MHz, CDCl3) δ 8.47 (d, J = 5.1 Hz, 1H), 8.05 (d, J = 8.5 Hz, 2H),
7.89 (d, J = 8.5 Hz, 2H), 7.82 (s, 1H), 7.45 (d, J = 7.4 Hz, 1H),
7.23−7.19 (m, 1H), 4.37 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz,
3H); 13C{1H} NMR (101 MHz, CDCl3) δ 195.3, 166.4, 151.3,
149.8, 142.2, 139.2, 134.9, 134.8, 130.8, 130.1, 129.1, 127.3, 126.9,
61.4, 14.5; IR (neat) 1720, 1603, 1443, 1280 cm−1; HRMS (ESI)
m/z: [M + H]+ calculated for C17H14NO3 280.0968; found
280.0961.
252.5 Hz), 144.3 (C-F, 5 JC‑F = 3.0 Hz), 139.1 (C-F, 5 JC‑F = 4.0
Hz), 135.9 (C-F, 4 JC‑F = 5.1 Hz), 135.5, 133.6 (C-F, 3 JC‑F = 7.1
Hz), 130.3, 130.0, 127.1, 123.7 (C-F, 3JC‑F = 8.1 Hz), 119.8 (C-F, 2
JC‑F = 23.2 Hz), 112.2 (C-F, 2 JC‑F = 25.3 Hz), 61.3, 14.5; IR (neat)
1709, 1603, 1477, 1277 cm−1; 19F NMR (376 MHz, CDCl3) δ
−110.22 to −110.39 (m, 1F); HRMS (ESI) m/z: [M + H]+
calculated for C18H14FO3 297.0921; found 297.0916.
Ethyl 4-(6-Methyl-1-oxo-1H-inden-2-yl)benzoate (2s). This
product was obtained as an amorphous red solid (0.044 g, 60%)
by using ethyl 4-((2-formyl-5-methylphenyl)ethynyl)benzoate (0.073
g, 0.25 mmol) and pyrrolidine (0.035 g, 0.5 mmol), and 1s (0.009
g) was recovered. Rf = 0.63 (PE/EtOAc = 5:1); mp 143−145 °C;
1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.7 Hz, 2H), 7.85 (d, J
= 8.6 Hz, 2H), 7.72 (s, 1H), 7.28 (s, 1H), 7.14 (d, J = 7.3 Hz, 1H),
6.98 (d, J = 7.3 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 2.33 (s, 3H),
1.38 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (101 MHz, CDCl3) δ
197.0, 166.6, 144.9, 140.8, 140.0, 136.1, 134.7, 134.4, 131.7, 130.0,
129.9, 127.1, 124.6, 122.5, 61.2, 21.7, 14.6; IR (neat) 1711, 1593,
1447, 1367, 1275 cm−1; HRMS (ESI) m/z: [M + H]+ calculated for
C19H17O3 293.1172; found 293.1166.
Ethyl 4-(6-Methoxy-1-oxo-1H-inden-2-yl)benzoate (2t). This
product was obtained as an amorphous purple solid (0.038 g,
49%) by using ethyl 4-((2-formyl-5-methoxyphenyl)ethynyl)-
benzoate (0.077 g, 0.25 mmol) and pyrrolidine (0.035 g, 0.5
mmol), and 1t (0.010 g) was recovered. Rf = 0.39 (PE/EtOAc =
1
Ethyl 4-(1-Oxo-5-(trifluoromethyl)-1H-inden-2-yl)benzoate (2z).
This product was obtained as an amorphous orange solid (0.041 g,
47%) by using ethyl 4-((2-formyl-4-(trifluoromethyl)phenyl)-
ethynyl)benzoate (0.087 g, 0.25 mmol) and pyrrolidine (0.036 g,
0.5 mmol). Rf = 0.61 (PE/EtOAc = 5:1); mp 156−158 °C; 1H
NMR (400 MHz, CDCl3) δ 8.06 (d, J = 8.5 Hz, 2H), 7.86 (d, J =
8.5 Hz, 2H), 7.80 (s, 1H), 7.57−7.52 (m, 2H), 7.33 (s, 1H), 4.37
(q, J = 7.1 Hz, 2H), 1.39 (t, J = 7.1 Hz, 3H); 13C{1H} NMR (101
MHz, CDCl3) δ 195.2, 166.4, 144.4, 143.4, 136.8, 136.0 (C-F, 2 JC‑F
5:1); mp 115−117 °C; H NMR (400 MHz, CDCl3) δ 8.01 (d, J =
8.3 Hz, 2H), 7.81 (d, J = 8.3 Hz, 2H), 7.70 (s, 1H), 7.04 (s, 1H),
6.97 (d, J = 7.9 Hz, 1H), 6.75 (dd, J = 7.9, 2.1 Hz, 1H), 4.35 (q, J
= 7.1 Hz, 2H), 3.80 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C{1H}
NMR (101 MHz, CDCl3) δ 196.4, 166.6, 161.5, 145.6, 136.1, 135.3,
134.2, 133.5, 129.9, 129.7, 126.8, 123.6, 117.0, 111.4, 61.2, 56.0,
14.5; IR (neat) 1711, 1594, 1484, 1280 cm−1; HRMS (ESI) m/z:
[M + H]+ calculated for C19H17O4 309.1121; found 309.1114.
6-(4-Nitrophenyl)-5H-indeno[5,6-d][1,3]dioxol-5-one (2u). This
product was obtained as an amorphous purple solid (0.043 g, 58%)
by using 6-((4-nitrophenyl)ethynyl)benzo[d][1,3]dioxole-5-carbalde-
hyde (0.074 g, 0.25 mmol) and pyrrolidine (0.035 g, 0.5 mmol). Rf
= 32.3 Hz), 135.0, 133.8, 130.8, 130.1, 127.5, 127.0 (C-F, 3 JC‑F
4.0 Hz), 123.6 (C-F, 1 JC‑F = 274.7 Hz), 123.3, 119.2 (C-F, 3 JC‑F
=
=
4.0 Hz), 61.4, 14.5; 19F NMR (376 MHz, CDCl3) δ −63.36 (s, 3F);
IR (neat) 1711, 1602, 1431, 1280 cm−1; HRMS (ESI) m/z: [M +
H]+ calculated for C19H14F3O3 347.0890; found 347.0886.
1
= 0.31 (PE/DCM = 1:1); mp 199−201 °C; H NMR (400 MHz,
CDCl3) δ 8.21 (d, J = 8.8 Hz, 2H), 7.93 (d, J = 8.7 Hz, 2H), 7.65
9462
J. Org. Chem. 2021, 86, 9455−9465